3 articles found
Browse Rainier Rehab's editorial coverage of Stimulant addiction. Our writers track federal and state policy, peer-reviewed research, treatment innovations, and frontline reporting from the addiction recovery field. Each article in this collection cites primary sources — government datasets (SAMHSA, NIH, CDC), Medicaid and Medicare bulletins, JAMA and Lancet studies, and on-the-record statements from clinicians, regulators, and people in recovery — so readers can verify claims and dig deeper.
We update this tag whenever new stimulant addiction reporting publishes. If you're a researcher, journalist, or family member trying to make sense of substance use disorder treatment, this is the working archive. For a directory of accredited treatment facilities, visit our facilities directory; to compare modalities, see our treatments overview and levels of care guide.
A randomized quadruple-blind trial found psilocybin-assisted therapy achieved 30% complete abstinence at 180 days vs 0% with placebo, with 72% reduced relapse risk.
Landmark UC San Diego study reveals first decline in all four waves of overdose epidemic, driven by falling fentanyl deaths, while stimulant-related fatalities continue rising.
Phase 3 study of 339 adults finds cheap, widely available medication cuts meth use by seven days per month, offering first pharmacological treatment option for stimulant use disorder.